Compare IMUX & EDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IMUX | EDF |
|---|---|---|
| Founded | 2016 | N/A |
| Country | United States | United States |
| Employees | 66 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 155.8M | 166.0M |
| IPO Year | 2013 | 2010 |
| Metric | IMUX | EDF |
|---|---|---|
| Price | $7.22 | $4.37 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 12 | 0 |
| Target Price | ★ $43.09 | N/A |
| AVG Volume (30 Days) | ★ 392.8K | 161.4K |
| Earning Date | 11-12-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 38.00 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.51 | $4.35 |
| 52 Week High | $17.43 | $5.67 |
| Indicator | IMUX | EDF |
|---|---|---|
| Relative Strength Index (RSI) | 33.34 | 30.26 |
| Support Level | $6.35 | N/A |
| Resistance Level | $8.60 | $5.41 |
| Average True Range (ATR) | 0.65 | 0.14 |
| MACD | 0.17 | -0.02 |
| Stochastic Oscillator | 36.89 | 3.35 |
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.
Virtus Stone Harbor Emerging Markets Income Fund is a closed-end management investment company. Its investment objective is to maximize total return, which consists of income from its investments and capital appreciation. The Fund normally will invest at least 80% of its net assets (plus any borrowings for investment purposes) in emerging markets securities.